Brice Gaudillière
YOU?
Author Swipe
View article: Guiding Parenteral Nutrition Therapy After Hematopoietic Stem Cell Transplantation
Guiding Parenteral Nutrition Therapy After Hematopoietic Stem Cell Transplantation Open
Adults undergoing hematopoietic cell transplantation often develop serious complications that cause rapid nutritional decline. We developed and evaluated an AI approach to standardize intravenous nutrition (total parenteral nutrition, TPN)…
View article: Palmar cooling mitigates exercise-induced immune suppression after high-intensity training: A randomized trial
Palmar cooling mitigates exercise-induced immune suppression after high-intensity training: A randomized trial Open
Objectives We investigated whether palmar cooling alters inflammatory responses following a single session of high-intensity eccentric exercise. We hypothesized that palmar cooling during rest intervals would attenuate maladaptive inflamma…
View article: An automated and scalable pipeline for high-dimensional immune cell phenotyping in mass cytometry datasets 2931
An automated and scalable pipeline for high-dimensional immune cell phenotyping in mass cytometry datasets 2931 Open
Description Efficient single-cell phenotyping has become essential for the identification of complex cell populations. Traditionally, these populations are identified through manual gating, a time-consuming process that is also subject to …
View article: Application of comprehensive multi-omic immune profiling strategy achieves superior checkpoint immunotherapy response prediction in lung cancer 3507
Application of comprehensive multi-omic immune profiling strategy achieves superior checkpoint immunotherapy response prediction in lung cancer 3507 Open
Description Immune checkpoint inhibitors (ICIs) are currently the most effective treatment for late-stage lung cancer. However, most patients fail to mount a durable response, and the mechanisms underlying non-responsiveness remain elusive…
View article: 116 Application of a comprehensive multi-omic immune profiling strategy achieves superior checkpoint immunotherapy response prediction in lung cancer
116 Application of a comprehensive multi-omic immune profiling strategy achieves superior checkpoint immunotherapy response prediction in lung cancer Open
View article: 85 Spatial intercellular associations in oral squamous cell carcinoma tumor immune microenvironment
85 Spatial intercellular associations in oral squamous cell carcinoma tumor immune microenvironment Open
View article: Table S1 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer
Table S1 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer Open
Clinical characteristics of patients with breast cancer & studies ID for Vg9Vd2 T cell profiling
View article: Table S5 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer
Table S5 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer Open
Differentially expressed genes between Vg9Vd2 T cells versus Vd1 T cell and abCD8 Tem in untreated primary breast tumors, related to Figure 2
View article: Table S3 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer
Table S3 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer Open
Gene characteristics of immune cell subsets in untreated primary TNBC, related to Figure 1
View article: Table S8 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer
Table S8 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer Open
Gene characteristics of Vg9Vd2 T cell subsets, related to Figure 3
View article: Figure S3 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer
Figure S3 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer Open
Integration of scRNA-seq datasets and annotation of immune cell subpopulations (related to Figure 1)
View article: Table S7 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer
Table S7 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer Open
GSEA outputs based on the differentially expressed genes between Vg9Vd2 T cells versus abCD8 TemraTex, abCD8 Tem and Vd1 T cell in primary breast tumors, related to Figure 2
View article: Table S6 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer
Table S6 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer Open
Mass cytometry panels, related to Figures 2 and 3
View article: Figure S8 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer
Figure S8 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer Open
Vg9Vd2 T cells display skewed differentiation profiles towards an early effector memory phenotype in untreated TNBC (related to Figure 3).
View article: Table S4 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer
Table S4 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer Open
Percentage of immune cell subsets in untreated primary TNBC, related to Figure 1
View article: Data from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer
Data from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer Open
Vγ9Vδ2 (TCRVγ9+ TCRVδ2+) T cells are promising immunotherapeutic targets with effective antitumor properties in both in vitro and preclinical models of triple-negative breast cancer (TNBC). However, no informat…
View article: Figure S10 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer
Figure S10 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer Open
LM22 transcriptomic signatures do not selectively identify intratumoral γδ T cells.
View article: Figure S2 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer
Figure S2 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer Open
Vg9Vd2 T cell identification in single–cell data (related to Figure 1).
View article: Single-cell-level digital twins for preterm birth prevention strategies
Single-cell-level digital twins for preterm birth prevention strategies Open
Digital twin models can accelerate therapeutic development by enabling low-risk testing of candidate interventions. In preterm labor (PTL), a major pregnancy complication where clinical trials face unique ethical and financial barriers, di…
View article: Figure S5 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer
Figure S5 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer Open
Vg9Vd2 T cells are transcriptionally armed for type–I antitumor cytotoxic activity in untreated TNBC (related to Figure 2)
View article: Table S9 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer
Table S9 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer Open
Pseudotime analysis of Vg9Vd2 T cells outputs, related to Figure 3
View article: Table S10 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer
Table S10 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer Open
LIANA interactome analysis of Vg9Vd2 T cells outputs, related to Figure 4
View article: Figure S4 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer
Figure S4 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer Open
Vγ9Vδ2 T cells are associated with better survival in TNBC (related to Figure 1).
View article: Table S13 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer
Table S13 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer Open
LASSO analysis of Vg9Vd2 T cells outputs, related to Figure 5
View article: Figure S9 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer
Figure S9 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer Open
Vg9Vd2 T cells are associated with better clinical responses to PD–(L)1 blockade therapy (related to Figure 5).
View article: Supplementary Materials from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer
Supplementary Materials from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer Open
Supplementary Materials
View article: Table S12 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer
Table S12 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer Open
GSEA outputs based on the differentially expressed genes between pre–αPD–1 versus post–αPD–1 Vg9Vd2 T cells in primary breast tumors, related to Figure 5
View article: Figure S6 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer
Figure S6 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer Open
Vg9Vd2 T cells are transcriptionally armed for type–I antitumor cytotoxic activity in untreated TNBC (related to Figure 2).
View article: Figure S7 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer
Figure S7 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer Open
Vg9Vd2 T cells display skewed differentiation profiles towards an early effector memory phenotype in untreated and PD–1 blockade–treated TNBC (scRNA–seq, related to Figure 3).
View article: Figure S1 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer
Figure S1 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer Open
Overview of the study design.